RESUMEN
BACKGROUND: Italy is presently facing an increase in immigration from sub-Saharan Africa through the Mediterranean Sea. Case reports of human cystic echinococcosis (CE) have been reported from most sub-Saharan countries. Therefore, an increase in the number of patients with CE coming from these areas in the Italian and European centers for infectious diseases is expected. Unfortunately, the epidemiology of CE in sub-Saharan countries is poorly known, which makes clinical suspicion and diagnosis of such infection difficult in patients coming from these areas. RESULTS: Here we report a case of hepatic CE in a patient from Niger who arrived in Italy through Libya and visited in a Tropical Medicine referral center in Northern Italy. The parasite was identified molecularly as the G6 "camel" strain of Echinococcus granulosus (E. canadensis). The diagnosis and management of a chronic and clinically complex infection like CE in such situation is difficult. Only 40 cases of CE from Niger have been reported; of these, 75% had extra-hepatic localization. To our knowledge, no strain characterization of human isolates from Niger has been reported so far. The CE cyst of the patient was in CE3a stage, indicating active transmission from the area in which the patient came. However, prevalence data from Niger, and from any other country in West Africa, are almost inexistent. CONCLUSIONS: We argue that population epidemiology surveys with ultrasound are warranted in Sahelian countries, including Niger. These studies could improve the knowledge of CE epidemiology, provide health authorities with important information for public health interventions targeting this zoonosis, and shed light on any difference between tissue tropism and clinical manifestations caused by the different E. granulosus strains.
Asunto(s)
Equinococosis Hepática/epidemiología , Echinococcus granulosus/aislamiento & purificación , Hígado/parasitología , Refugiados , Adulto , Animales , Equinococosis Hepática/diagnóstico , Equinococosis Hepática/parasitología , Equinococosis Hepática/transmisión , Echinococcus granulosus/clasificación , Echinococcus granulosus/genética , Echinococcus granulosus/fisiología , Humanos , Italia , Libia/epidemiología , Hígado/patología , Masculino , Mar Mediterráneo , Niger/epidemiología , Prevalencia , ZoonosisRESUMEN
In a multicentre, open-label, clinical trial, 43 patients virologically suppressed while receiving a standard triple antiretroviral therapy were randomized (1:1:1) to switch to monotherapy with darunavir/ritonavir (DRV/r-MT arm), monotherapy with lopinavir/ritonavir (LPV/r-MT arm) or to continue on the ongoing regimen (cART arm). The proportion (95% CI) of patients with virological success (Snapshot analysis) at week 48 was 73% (48%-90%) in the DRV/r-MT arm, 69% (42%-88%) in the LPV/r-MT arm and 87% (61%-98%) in the cART arm. Virological failure was detected in only one patient receiving LPV/r-MT. The LPV/r-MT arm showed a modest worsening in lipid profile.
Asunto(s)
Darunavir/uso terapéutico , Infecciones por VIH/tratamiento farmacológico , Lopinavir/uso terapéutico , Ritonavir/uso terapéutico , Adulto , Fármacos Anti-VIH/uso terapéutico , Terapia Antirretroviral Altamente Activa , Darunavir/administración & dosificación , Femenino , Humanos , Lopinavir/administración & dosificación , Masculino , Persona de Mediana Edad , Ritonavir/administración & dosificaciónRESUMEN
In a retrospective study concerning the epidemiology of extended-spectrum beta-lactamase (ESBL) positive Enterobacteriaceae during 2007-2008 in the wards of the Carlo Poma hospital in Mantova, Mercurio surveillance software was used to detect alert microorganisms. Our objective was to link the epidemiological data with the type of patient and ward, and to assess the risk factors for such infections in particular nosocomial environments. The study enabled the change in the relative epidemiological data to be detected, and showed that such bacteria can be found almost throughout the hospital.
Asunto(s)
Proteínas Bacterianas/análisis , Infección Hospitalaria/epidemiología , Infecciones por Enterobacteriaceae/epidemiología , Enterobacteriaceae/aislamiento & purificación , Hospitales Urbanos/estadística & datos numéricos , Resistencia betalactámica , beta-Lactamasas/análisis , Adulto , Infección Hospitalaria/microbiología , Enterobacteriaceae/enzimología , Infecciones por Enterobacteriaceae/microbiología , Escherichia coli/enzimología , Escherichia coli/aislamiento & purificación , Infecciones por Escherichia coli/epidemiología , Infecciones por Escherichia coli/microbiología , Departamentos de Hospitales/estadística & datos numéricos , Humanos , Vigilancia Inmunológica , Recién Nacido , Unidades de Cuidado Intensivo Neonatal/estadística & datos numéricos , Italia/epidemiología , Klebsiella/enzimología , Klebsiella/aislamiento & purificación , Infecciones por Klebsiella/epidemiología , Infecciones por Klebsiella/microbiología , Proteus/enzimología , Proteus/aislamiento & purificación , Infecciones por Proteus/epidemiología , Infecciones por Proteus/microbiología , Especificidad por SustratoRESUMEN
We compare epidemiological data from two twelve-month periods, before and after the introduction of preoperative antibiotic prophylaxis guidelines at Carlo Poma hospital in Mantova, Italy, in June 2003. Considering the results from the microbiology laboratory and the data from the pharmacy, concerning the consumption of some antimicrobials, we noted a significant decrease in the incidence of methicillin-resistant Staphylococcus aureus (MRSA) in surgical wards, where the incidence of MRSA had previously exceeded that in medical wards. At the same time, analysis of antibiotic consumption revealed a considerable decrease in third and fourth-generation cephalosporins and an increasing use of cephazolin, in compliance with prophylaxis protocol rules. This trend was confirmed by analysis of the same data regarding the first six months of 2006.
Asunto(s)
Profilaxis Antibiótica , Cefalosporinas/uso terapéutico , Infección Hospitalaria/epidemiología , Adhesión a Directriz/estadística & datos numéricos , Complicaciones Posoperatorias/epidemiología , Medicación Preanestésica , Infecciones Estafilocócicas/epidemiología , Profilaxis Antibiótica/estadística & datos numéricos , Cefalosporinas/administración & dosificación , Cefalosporinas/clasificación , Infección Hospitalaria/prevención & control , Utilización de Medicamentos/estadística & datos numéricos , Humanos , Incidencia , Italia/epidemiología , Resistencia a la Meticilina , Complicaciones Posoperatorias/prevención & control , Guías de Práctica Clínica como Asunto , Medicación Preanestésica/estadística & datos numéricos , Estudios Retrospectivos , Infecciones Estafilocócicas/prevención & control , Staphylococcus aureus/efectos de los fármacos , Staphylococcus aureus/aislamiento & purificación , Servicio de Cirugía en Hospital/estadística & datos numéricosRESUMEN
HIV-infected patients may undergo renal damage related to the HIV infection itself, to the presence of co-infections, arterial hypertension, diabetes or to the exposure to nephrotoxic drugs. Tenofovir has been associated with the development of acute renal failure with Fanconi syndrome and acute tubular necrosis and, albeit rarely, with chronic liver disease. Patients with low CD4 cell count, low body weight and with concomitant diseases such as arterial hypertension and diabetes or co-infections with HCV, HBV or Treponema pallidum seem at higher risk of tenofovir-related nephrotoxicity. Other risk factors include previous exposure to nephrotoxic drugs and the association of tenofovir with boosted protease inhibitors or with didanosine. However, from the analysis of published papers the incidence of tenofovir-related renal toxicity seems low, as confirmed also by our personal casuistry (SCOLTA Project). Thus, a careful selection of patients including the evaluation of existent renal disease before starting an antiretroviral regimen including tenofovir is necessary to prevent renal damage. Furthermore, frequent monitoring of renal function in patients at higher risk of renal damage is strongly recommended, as well as a tenofovir dose adjustment if an alteration of renal function is detected.
Asunto(s)
Adenina/análogos & derivados , Fármacos Anti-VIH/efectos adversos , Terapia Antirretroviral Altamente Activa/efectos adversos , Infecciones por VIH/tratamiento farmacológico , Enfermedades Renales/inducido químicamente , Organofosfonatos/efectos adversos , Adenina/efectos adversos , Interacciones Farmacológicas , Humanos , TenofovirRESUMEN
OBJECTIVE: To assess the impact of highly active antiretroviral therapy (HAART) on health resource utilisation (HRU) and to estimate associated direct costs in a population based setting. DESIGN: Retrospective study of all patients in the Institute of Infectious and Tropical Diseases (Brescia, Northern Italy) during a 4 years period related to the prescription of HAART has been performed: from 1997 (before HAART) to 2000 (after substantial period of HAART prescription). MAIN OUTCOME MEASURES AND RESULTS: HIV inpatient admissions (IA's) decreased from 506.8/1000 patients (pts) in 1997 to 246.3/1000 pts in the year 2000. Day care admissions (DCA's) also decreased from 1658.3/1000 pts to 942/1000 pts, while outpatient consultations (OC's) increased from 2046.9/1000 pts to 2590.6/1000 pts in the same years, respectively. By contrast, a relative increase of IA's and DCA's of patients whose serostatus was HIV-negative or unknown has been found. Cost of antiretroviral therapy increased by 2582 Euro (2272 US Dollars), while cost of HIV care (IA+DCA+OC) decreased by 1546 Euro (1360.4 US Dollars) per patient, resulting in a saving in direct cost equal to 60% of the increase in the expenditure for antiretroviral drugs. CONCLUSIONS: Our results demonstrate the shift of HIV care from inpatient to outpatient services that occurred after HAART had been introduced into clinical practice. Despite persisting clinical benefits, an increase in total direct cost for HIV pts has been seen for the first time during the HAART era in the year 2000, probably due to an over-prescription of HAART, according to actual Guideline for antiretroviral therapy use, to pts who were not at risk of clinical progression in the short term. Pharmacoeconomical surveillance of HAART is necessary while a favourable impact on the saving in cost is expected from the new treatment guidelines that suggest a relative delay in starting HAART.
Asunto(s)
Terapia Antirretroviral Altamente Activa/economía , Infecciones por VIH/tratamiento farmacológico , Recursos en Salud/estadística & datos numéricos , Atención Ambulatoria/economía , Atención Ambulatoria/estadística & datos numéricos , Fármacos Anti-VIH/economía , Fármacos Anti-VIH/uso terapéutico , Grupos Diagnósticos Relacionados , Economía Farmacéutica , Infecciones por VIH/economía , Infecciones por VIH/epidemiología , Recursos en Salud/economía , Recursos en Salud/provisión & distribución , Investigación sobre Servicios de Salud , Hospitalización/economía , Hospitalización/tendencias , Humanos , Italia/epidemiología , Estudios RetrospectivosRESUMEN
Since it has been demonstrated that concomitant infections could influence the outcome of antiviral treatment, we investigated whether the presence of SENV infection may interfere with highly active antiretroviral therapy (HAART) in HIV+ coinfected patients. In spite of persistent fluctuations in SENV-A positivity we could not find any correlation between SENV-DNA and the immunological and virologic parameters found in the patients, suggesting SENV has no apparent clinical relevance during highly active antiretroviral therapy.